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ScienceDirectUnderstanding mechanisms that control immunity is central in
the quest to gain insights into the etiopathology of many of the
diseases that afflict modern societies. New results implicate the
nervous system as a central player in controlling many aspects
of both the innate and adaptive arms of the immune response.
Furthermore it is now well appreciated that a novel group
of autacoids termed as specialized proresolving mediators,
which are enzymatically produced from essential fatty acids,
orchestrate the immune response promoting the termination of
inflammation as well as tissue repair and regeneration. The
present brief review discusses evidence for the crosstalk
between the nervous system and leukocytes in regulating SPM
production. We will also discuss the impact that this has on
controlling tissue resolution tone and the resolution of both
infectious and sterile inflammation.
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Introduction
The nervous system integrates signals from the periphery
to ensure homeostatic control and host survival. Increas-
ing evidence demonstrates that in addition to regulating
sensory and motor functions the nervous system is also
essential in regulating the host immune response [1].
This crosstalk between the immune and nervous systems
is a primordial defense mechanism where, for example,
in the nematode Caenobacter elegans the nervous system is
central in controlling innate immunity via the modula-
tion of the non-canonical unfolded protein response [2].
In mammals the nervous system is also important inCurrent Opinion in Immunology 2018, 50:48–54 controlling both the innate and adaptive arms of the
immune responses [1,3,4]. Recent studies demonstrate
that the vagus nerve orchestrates host responses to both
sterile, including sterile peritonitis [5], arthritis [6], colitis
[7] and cancer [4] as well as infectious insults, for example,
polymicrobial sepsis [8] and Escherichia coli infections [3].
These observations have been extended to humans where
in patients with arthritis stimulation of the vagus system
leads to a significant reduction in disease activity and in
circulating markers of inflammation [9].
Efforts to identify signals that control the termination of
inflammation recently uncovered a genus of mediators
that are produced via the stereoselective conversion of
essential fatty acids. These autacoids activate cognate
receptors and regulate the biological actions of both
innate and adaptive immune cells [10]. Given their potent
actions and unique structures these mediators are coined
as specialized pro-resolving mediators (SPM). This super-
family of mediators is composed of four main families: the
arachidonic acid derived lipoxins, the eicosapentaenoic
acid (EPA), n3 docosapentaenoic acid (DPA) and doc-
osahexaenoic acid (DHA)-derived resolvins (Rv) and the
n3 DPA and DHA-derived protectins (PD) and mar-
esins (MaR) (see [11,12] for a detailed review of their
biosynthetic pathways). The production of these media-
tors is regulated in both a temporal and tissue dependent
manner. Recent studies demonstrate that the biological
actions of RvD1 (see Table 1 for complete stereochemis-
try), a DHA-derived SPM, are additive to those of anti-
biotics reducing the required doses to clear both gram
positive and negative infections [13]. These mediators
also regulate tissue repair and regeneration by controlling
leukocyte trafficking, phenotype, the expression of genes
that are involved in the regeneration of damaged tissues
and the re-establishment of barrier function [14–16].
Impaired LXA4 production is associated with dysregu-
lated T-cell response in dry eye disease [17]. RvD1,
RvD2 and MaR1 also regulate T-cell phenotype,
down-regulating the production of effector cytokines,
including IFNg, in both CD4 and CD8 positive T-cells.
They also promote the expression of FoxP3 in CD4
cells [18]. The RvD series precursor 17-HDHA regu-
lates B-cell responses to viral infections,  up-regulating
antibody production and protecting against influenza
infections [19] and pain [20,21]. The EPA derived
RvE1 regulates the responses of antigen presenting
cells, including those of dendritic cells reducing the
expression of IL-12 [22,23]. Together these findings
emphasize the role of this new super-family ofwww.sciencedirect.com
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Table 1
Lipid mediator metabolomes, abbreviations and complete stereochemistry.
Metabolome Mediator Abbreviation Stereochemistry
DHA Resolvin D1 RvD1 7S, 8R, 17S-trihydroxy-4Z, 9E, 11E, 13Z, 15E, 19Z-
docosahexaenoic acid
Resolvin D2 RvD2 7S, 16R, 17S-trihydroxy-4Z, 8E, 10Z, 12E, 14E, 19Z-
docosahexaenoic acid
Resolvin D3 RvD3 4S, 11R, 17S-trihydroxy-5Z, 7E, 9E, 13Z, 15E, 19Z-
docosahexanoic acid
Resolvin D4 RvD4 4S, 5R, 17S-trihydroxy-6E, 8E, 10Z, 13Z, 15E, 19Z-
docosahexaenoic acid
Resolvin D5 RvD5 7S, 17S-dihydroxy-4Z, 8E, 10Z, 13Z, 15E, 19Z-
docosahexaenoic acid
Maresin 1 MaR1 7R, 14S-dihydroxy-4Z, 8E, 10E, 12Z, 16Z, 19Z-
docosahexaenoic acid
Protectin conjugate in tissue regeneration 1 PCTR1 16R-glutathionyl, 17S-hydroxy-4Z, 7Z, 10Z, 12E, 14E,
19Z-docosahexaenoic acid
Protectin conjugate in tissue regeneration 2 PCTR2 16-cysteinylglycinyl, 17S-hydroxy-4Z, 7Z, 10Z, 12, 14,
19Z-docosahexaenoic acid
Protectin conjugate in tissue regeneration 3 PCTR3 16-cysteinyl, 17S-hydroxy-4Z, 7Z, 10Z, 12, 14, 19Z-
docosahexaenoic acid
EPA Resolvin E1 RvE1 5S, 12R, 18R-trihydroxy-6Z, 8E, 10E, 14Z, 16E-
eicosapentaenoic acid
AA Lipoxin A4 LXA4 5S, 6R, 15S-trihydroxy-7E, 9E, 11Z, 13E-eicosatetraenoic
acid
Leukotriene B4 LTB4 5S, 12R-dihydroxy-6Z, 8E, 10E, 14Z-eicosatetraenoic
acid
Prostaglandin E2 PGE2 9-oxo-11R, 15S-dihydroxy-5Z, 13E-prostadienoic acidautacoids in the maintenance of homeostasis and re-
establishment of function following challenge, whether
this is sterile or infective in nature.
Several mechanisms are now implicated in the regulation
of SPM biosynthesis; regulation of micro RNA 219 controls
5-LOX expression [24]. Post-translation modification of 5-
LOX leads to a switch in the product profile of the enzyme
from the pro-inflammatory leukotriene (LT) B4 to the pro-
resolving mediator LXA4 [25]. Sex hormones also play an
important role in regulating SPM production, an action that
is also tissue dependent, where for example in murine
systems estrogen down-regulates LXA4 production in the
eye [17]. In humans this hormone is associated with an
increased derman and systemic SPM production including
RvD, LX and RvE [26]. Recent results also demonstrate
that the nervous system is essential in controlling local
SPM formation, during both infectious and sterile inflam-
mation [3,5]. The present review highlights the recent
evidence underpinning the role of the nervous system in
regulating tissue SPM production and the role of this
response in controlling innate immune responses to both
sterile and infectious insults.
Neuronal regulation of tissue lipid mediator
profiles
Increasing evidence indicates that the initial response by
resident leukocytes to both injury and infections has a
significant bearing on outcome of the ensuing inflamma-
tion and whether this resolves or becomes chronic [27].www.sciencedirect.com Given the roles that the vagus nerve plays in regulating
host immune responses [1,8,9], we recently queried
whether this nerve was also involved in the tempering
of tissue leukocyte phenotype and responses. Using a
systematic approach we found that cervical disruption of
the vagus nerve lead to a shift in peritoneal concentrations
of both pro-resolving as well as inflammation initiating
eicosanoids [3]. Peritoneal prostaglandin concentrations
were increased in vagotomised mice whereas concentra-
tions of several pro-resolving mediators including the
recently uncovered immunoresolvents Protectin Conju-
gates in Tissue Regeneration (PCTR) were decreased. Of
note, cervical disruption of the left vagus did not signifi-
cantly perturb peritoneal PCTR levels suggesting that
the neuro-immune plexus was in this organ was associated
with the right vagus. These changes in peritoneal lipid
mediator concentrations point to a significant alteration in
the ability of the host to mount a protective immune
response given the increase in inflammation-initiating
eicosanoids and a decrease in the tissue protective med-
iators; a lipid mediator profile associated with delayed/
non-resolving inflammation [10,28,29].
Vagus regulates PCTR biosynthesis in
peritoneal ILC-3 and macrophages
Changes in peritoneal levels of these mediators were also
associated with an alteration peritoneal leukocyte com-
position, phenotype and functions. Loss of vagal signaling
impacted group 3 innate lymphoid cells (ILC-3). The
observation that ILC-3 numbers were significantlyCurrent Opinion in Immunology 2018, 50:48–54
50 Innate immunitydecreased in the peritoneum of vagotomised mice
demonstrates that the biological actions of these cells
are not solely restricted to the gastro-intestinal epithe-
lium. Our studies demonstrated that these cells are also
found in milky spots within the greater omenutm in
proximity to macrophages as well as neuronal bodies
arising from the gastroepiploic nerve; a nerve that is
linked to the right vagus nerve via the gastroepiploic
plexus [30]. This highlights a role for neuronal signaling
in controlling ILC-3 trafficking to organs, given the
decreased peritoneal cell counts observed following
resection of the vagal trunk [3]. These findings are in
accord with recent studies demonstrating a role of the
neuronal system in regulating ILC-3 responses. Disrup-
tion of vagal signaling also impacted the peritoneal mac-
rophage population. Peritoneal macrophage numbers
were increased in vagotomise mice, with a shift in bothFigure 1
The PCTR biosynthetic pathway and biological actions. In the production of
4Z,7Z,10Z,13Z,15E,19Z-docosahexaenoic acid. This is subsequently conve
of hydrogen from carbon 14 yielding 16S,17S-epoxy-4Z,7Z,10Z,12E,14E,19
these reactions are catalyzed by the 12/15-LOX exnyme. The epoxide is su
glutathionyl,17S-hydroxy-4Z,7Z,10Z,12E,14E,19Z-docosahexaenoic acid (PC
4Z,7Z,10Z,12,14,19Z-docosahexaenoic acid (PCTR2) which in turn is precu
docosahexaenoic acid (PCTR3). The PCTRs carry potent biological actions 
leukocyte trafficking and the uptake and killing of bacteria as well as tissue
Current Opinion in Immunology 2018, 50:48–54 the expression of lineage markers, including arginease-1
and major histocompatibility complex II, as well as lipid
mediator profiles. Of note, the biosynthesis of PCTRs in
these peritoneal macrophages was altered indicating that
vagal signaling controls macrophage lipid mediator bio-
synthesis. The role of ILC-3 in regulating both peritoneal
PCTR concentrations as well as macrophage phenotype
was highlighted by the observation that both were altered
in Rag1/ mice when ILC-3 were depleted using an
anti-CD90 antibody. In both WT and Rag1/ mice loss
of ILC-3 also lead to a delay in resolution responses to
Escherichia coli infections and an impaired ability of peri-
toneal leukocytes to clear bacteria [3]. Recent studies
have also demonstrated an interaction between compo-
nents of the neuronal system and ILC-3 [31,32] as well as
other immune cells including macrophages [33,34] in
controlling host response to both sterile and infectiousCurrent Opinion in Immunology
 PCTRs DHA is oxygenated at carbon 17 to yield 17S-hydro(peroxy)-
rted to an allylic epoxide intermediate via 15-LOX mediated abstraction
Z-docosahexaenoic acid (16S, 17S-epoxy-PD). In murine systems
bstrate for conversion to the peptide–lipid conjugated mediator 16R-
TR1) that is precursor to 16-cysteinylglycinyl,17S-hydroxy-
rsor to 16-cysteinyl,17S-hydroxy-4Z,7Z,10Z,12,14,19Z-
in promoting the resolution of infectious inflammation by regulating
 repair and regeneration.
www.sciencedirect.com
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a central role for neuronal control of immune responses in
regulating in the maintenance of tissue homeostasis and
the re-establishment of function following an inflamma-
tory episode.
In the lamina propria ILC-3 are central in regulating
tissue macrophage responses by producing regulatory
factors such as GM-CSF, a mechanism that can be either
protective [35] or pathogenic [36]. These cells also
express 15-LOX type 1 (mouse cells express the homol-
ogous enzyme: 12/15-LOX), the initiating enzyme in the
PCTR biosynthetic pathway, and the activity of this
enzyme is upregulated by the neurotransmitter acetyl-
choline [3]. PCTRs are a newly uncovered family of pro-
resolving mediators that control neutrophil and macro-
phage responses to both sterile and infectious stimuli.
This family of mediators is biosynthesized via the insertion
of molecular oxygen by 15-liopxygenase at carbon 17 of
DHA to yield 17S-hydro(peroxy)-4Z,7Z,10Z,13Z,15E,19Z-
docosahexaenoic acid. This is subsequently converted to an
allylic epoxide intermediate via 15-LOX mediated abstrac-
tion of hydrogen from carbon 14 yielding 16S, 17S-epoxy-
4Z,7Z,10Z,12E,14E,19Z-docosahexaenoic acid (16S, 17S-
epoxy-PD; Figure 1). The epoxide is substrate for conver-
sion by glutathione-S-transferases to the peptide–lipid
conjugated mediator 16R-glutathionyl, 17S-hydroxy-
4Z,7Z,10Z,12E,14E,19Z-docosahexaenoic acid (PCTR1)
that is precursor to 16-cysteinylglycinyl, 17S-hydroxy-
4Z,7Z,10Z,12,14,19Z-docosahexaenoic acid (PCTR2)Figure 2
PCTR mediate neuronal control of tissue resolution tone. Neuronal singling 
macrophage phenotype, upregulating macrophage SPM biosynthesis and r
www.sciencedirect.com and 16-cysteinyl, 17S-hydroxy-4Z,7Z,10Z,12,14,19Z-doc-
osahexaenoic acid (PCTR3). Each of these mediators
promotes the phagocytosis of bacteria by neutrophils
and macrophages as well as macrophage efferocytosis
[37–39]. PCTR1 downregulates the production of
inflammatory cytokines by macrophages including
tumor necrosis factor-a, Interleukin (IL)-3, IL-8, and
IL-12(p40) and regulate leukocyte trafficking increasing
monocyte/macrophage trafficking and limiting neutro-
phil recruitment to the site of inflammation [39]. In
addition, each of the PCTRs accelerates tissue regener-
ation in planaria [37,38].
Given that leukocytes are central in SPM biosynthesis,
loss of PCTRs in mice following the disruption of peri-
toneal neuronal signaling indicates that the neuro-
immune plexus is essential for controlling PCTR biosyn-
thesis in peritoneal leukocytes. In this context production
of SPM, in particular PCTR1, by ILC-3 is central in
regulating peritoneal macrophage phenotype and
responses whereby co-incubations of peritoneal macro-
phages with either ILC-3 or PCTR1 restores their lipid
mediator profiles and their ability to uptake bacteria
(Figure 2). This was of biological relevance in infections
since reconstitution of vagotomised mice with either
ILC-3 or PCTR1 also lead to a restoration of host
responses following E. coli inoculation, significantly
reducing the number of leukocytes recruited to the
peritoneal cavity, shortening the resolution interval (i.e.
the time it takes for recruited neutrophils to traffic out ofCurrent Opinion in Immunology
in the peritoneum regulates ILC-3 PCTR production that controls
egulating host responses to bacterial infection.
Current Opinion in Immunology 2018, 50:48–54
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Figure 3
Current Opinion in Immunology
Temporal regulation of exudate SPM biosynthesis during self-limited infections. Under ideal conditions neuronal signal regulates tissue PCTR
biosynthesis. This controls tissue resident macrophage phenotype and function. Infectious challenge activates resident leukocytes, primarily
macrophages, and upregulates maresin (MaR)1 biosynthesis, this mediator promotes the uptake and clearance of apoptotic cells and bacteria and
antagonizes the signaling of the leukocyte chemoattractant LTB4 by acting as a partial agonist/antagonist to the LTB4 receptor (BLT1). This
regulatory action is also shared with the MaR1 further metabolite 22-OH-MaR1 [43]. As inflammatory exudate matures neutrophil numbers reach a
maximum and a shift in the lipid mediator profile occurs with an upregulation in RvD5 and PD1 concentrations that denotes the onset of resolution
[13]. This shift in lipid mediator profile is also associated with an increased recruitment of monocytes to the peritoneum and an increase in the
number of resolution phase macrophages. During these late stages of inflammation-resolution there is also the formation of tissue-reparative and
regenerative mediators termed as maresin conjugates in tissue regeneration (MCTRs) [15]. The biosynthesis of these mediators in human
macrophages is initiated via the 14-lipoxygenation of DHA, to yield three novel peptide–lipid conjugated mediators namely MCTR1, MCTR2 and
MCTR3 [15].the peritoneum) and upregulated the ability of peritoneal
leukocytes to phagocytose and kill bacteria [3]. Further-
more, it rectified LM-SPM biosynthesis during the course
of the inflammatory response. Given the role that differ-
ent SPM play in regulating distinct aspects of the host
immune response during select stages of infectious-
inflammation this is critical for the re-establishment of
function (see [28] for a detailed review and Figure 3).
Therefore these findings underscore the role of ILC-3 in
orchestrating peritoneal macrophage responses and tissue
resolution tone. They also highlight that dysregulation in
SPM production alters leukocyte phenotype and conse-
quently function.Current Opinion in Immunology 2018, 50:48–54 SPM regulation by the vagus in sterile
inflammation
The regulation of lipid mediators by neuronal circuits is
also central in the control of inflammation to sterile injury.
The vagus nerve regulates the expression of the axonal
guidance molecule netrin 1, a protein that in addition to
regulating neuronal development also controls immune
responses [5,40,41]. Incubation of netrin 1 with primary
human monocytes upregulates the biosynthesis of several
pro-resolving mediators including RvD1 and
LXA4. Netrin 1 also increases SPM production in vivo
during acute-self limited inflammation, were this protein
upregulates exudate RvD5 and PD1 concentrationswww.sciencedirect.com
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1 expression in both vagotomized mice and netrin 1 het-
erozygote mice lead to dysregulated LM production
following sterile challenged, including a reduction in
exudate RvD1 and an increase in the inflammation initi-
ating eicosanoids LTB4 and PGE2 [5]. This was also
associated with a disruption of resolution processes,
increased neutrophil recruitment to the peritoneum,
delayed resolution of inflammation and an increase in
the exudate levels of several pro-inflammatory cytokines
including TNF-a, IL-6 and MIP-1a [5]. Of note, netrin
1 also regulates macrophage efferocytosis, an action that
was dependent on the ability of these cells to produce
SPM, given that this action was lost in macrophages from
12/15-LOX deficient mice (see Figure 2). In addition,
administration of RvD1 to netrin deficient mice restored
resolution responses, reducing the amplitude as well as
the duration of the inflammatory response [5].
Concluding remarks
The biological actions of SPM are now appreciated to be
relevant to many experimental as well as human settings
where they regulate the cardinal signs of resolution that
include remotio infectiones agens (clearance of infective
agents), remotio obruta (clearance of debris), avaritiam
ex munere (gain of function) and indolentia (analgesia)
[37,38]. Dysregulation in the production of these media-
tors is also associated with the development of disease
[11,12,14,29,37,38,42] with the mechanisms leading to
this impaired production remaining of interest. Thus,
the appreciation that the neuro-immune synapse is impor-
tant in regulating tissue levels of these mediators, with
neurotransmitters such acetylcholine being important in
controlling local SPM biosynthesis, may provide new leads
in the understanding of disease mechanisms. Moreover,
these new links to neural immune networks represent new
leads in the development of approaches that harness the
potent biological actions of SPM and do not carry the many
side effects associated with current therapeutics.
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